Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2005-02-10
2008-03-18
Hartley, Michael G. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C514S248000, C544S239000
Reexamination Certificate
active
07344702
ABSTRACT:
The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
REFERENCES:
patent: 5087440 (1992-02-01), Cacheris
patent: 5088499 (1992-02-01), Unger
patent: 5155215 (1992-10-01), Ranney
patent: 5169848 (1992-12-01), Bettarini et al.
patent: 5228446 (1993-07-01), Unger et al.
patent: 5281704 (1994-01-01), Love et al.
patent: 5412148 (1995-05-01), Keana
patent: 5417959 (1995-05-01), Wallace
patent: 5520904 (1996-05-01), Nosco et al.
patent: 5547656 (1996-08-01), Unger
patent: 5567411 (1996-10-01), Keana et al.
patent: 5585112 (1996-12-01), Unger et al.
patent: 5679810 (1997-10-01), Love et al.
patent: 5760191 (1998-06-01), Snow et al.
patent: 5801228 (1998-09-01), Hollister et al.
patent: 5804161 (1998-09-01), Long et al.
patent: 5846517 (1998-12-01), Unger
patent: 2003/0044354 (2003-03-01), Carpenter, Jr. et al.
patent: 2004/0033197 (2004-02-01), Madar et al.
patent: 2004/0034239 (2004-02-01), Nicolaou et al.
patent: 2005/0244332 (2005-11-01), Radeke et al.
patent: 0727225 (1996-08-01), None
patent: WO 91/14460 (1991-10-01), None
patent: WO 92/17215 (1992-10-01), None
patent: WO94/22496 (1994-10-01), None
patent: WO 02/20008 (2002-03-01), None
patent: WO 03/086476 (2003-10-01), None
Schuler et al., Biochimica et Biophysica Acta, 2001, 1506, p. 79-87.
Walker, John E., “The NADH: ubiquinone oxidoreductase (complex I) of respiratory chains,” Quarterly Review of Biophysics, vol. 25, No. 3, pp. 253-324 (1992).
Esposti, Mauro D., “Inhibitors of NADH—ubiquinone reductase: an overview,” Biochimica et Biophysica Acta, vol. 1364, pp. 222-235 (1998).
Brown, Michael et al., “Delineation of myocardial oxygen utilization with carbon -11—labeled acetate,” Circulation, vol. 76, No. 3, pp. 687-696 (1987).
Krivokapich, Janine et al., “13N Ammonia Myocardial Imaging at Rest and With Exercise in Normal Volunteers, Quantification of Absolute Myocardial Perfusion With Dynamic Positron Emission Tomography,” Circulation, vol. 80, No. 5, pp. 1328-1337 (1989).
Pauwels, E.K.J. et al., “Fluorine-18-radiolabeled pharmaceuticals for imaging with positron emission tomography, excluding [18F]-fluorodeoxyglucose,” Drugs of the Future, vol. 27, pp. 655-667 (2002).
Magerstadt, Michael et al., “Gd(DOTA): An Alternative to Gd(DTPA) as a T1,2 Relaxation Agent for NMR Imaging of Spectroscopy,” Magnetic Resonance in Medicine, vol. 3, pp. 808-812 (1986).
Runge, Val M. et al., “MR Imaging of Rat Brain Glioma: Gd-DTPA versus Gd-DOTA.” Radiology, vol. 166, No. 3, pp. 835-838 (1988).
Bousquet, Jean-Claude, et al., “Gd-DOTA: Characterization of a New Paramagnetic Complex,” Radiology, vol. 166, No. 3, pp. 693-698 (1988).
Nicolaou, KC, et al., “Combinatorial synthesis of novel and potent inhibitors of NADH:ubiquinone oxidoreductase,” Chemistry & Biology, vol. 7, pp. 979-992, (2000).
Lindell, Stephen D. et al, “The design and synthesis of novel inhibitors of NADH:ubiquinone oxidoreductase,” Bioorganic & Medicinal Chemistry Letters, vol. 14, pp. 511-514 (2004).
Azure Michael T.
Casebier David S.
Dischino Douglas D.
Purohit Ajay
Radeke Heike S.
Bristol-Myers Squibb Pharma Company
Chapman Jennifer C.
Hartley Michael G.
Levis John F.
Mingo Pamela A.
LandOfFree
Contrast agents for myocardial perfusion imaging does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Contrast agents for myocardial perfusion imaging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Contrast agents for myocardial perfusion imaging will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3962181